Earnings ·
Minerva Neurosciences reported financial results for the quarter ended June 30, 2026
NERVMinerva Neurosciences, Inc.
Minerva Neurosciences reported financial results for the quarter ended June 30, 2026. The company recorded a GAAP net income of $17.5 million ($0.36 per basic share), driven by a $27.6 million non-cash gain on the change in fair value of its warrant liability; adjusted non-GAAP net loss was $7.8 million. Cash, cash equivalents, and marketable securities totaled approximately $75.4 million at June 30, 2026. The company confirmed that its confirmatory Phase 3 trial (C19 Study) for roluperidone is ongoing, with topline efficacy data expected in the second half of 2027. Minerva Neurosciences operates as a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders.